Short-term cholesterol feeding has been shown to cause impaired vasodilatation in response to acetylcholine. The present study of renal hemodynamics was carried out to examine the role of thromboxane/PGH2 in mediating this abnormal response. In normal rats (ND), infusion of acetylcholine into the suprarenal aorta caused marked increases in renal blood flow, GFR, single nephron glomerular filtration rate, single nephron afferent plasma flow, and ultrafiltration coefficient, accompanied by a fall in preglomerular resistance. In cholesterol fed rats (CSD), the response to acetylcholine was markedly blunted. Infusion of L-arginine, the precursor to nitric oxide (NO), caused comparable renal vasodilatation in ND and CSD rats, implying that the ability to synthesize NO from its precursor was not severely impaired in the CSD animals. The observations do not exclude, however, the possibility of impaired synthesis of NO from endogenous precursor. In additional experiments, we infused a TxA2/PGH2 receptor antagonist in CSD rats and then administered acetylcholine. Renal vasodilatation occurred to a degree indistinguishable from that in ND rats given acetylcholine alone. When ND rats were infused with the same combination of the TxA2/PGH2 receptor antagonist and acetylcholine, renal vasodilatation was also significantly greater than with acetylcholine alone. This suggests that acetylcholine initiates release of vasoconstrictor prostanoids as well as NO from vascular endothelium. This was observed in ND as well as in CSD animals. Because LDL increases the supply of arachidonic acid for prostaglandin synthesis, we postulate that greater amounts of PGH2/TxA2 are synthesized via calcium activation of phospholipase A2 when acetylcholine is administered to CSD animals. This may account in large measure for the blunted vasodilatation to acetylcholine. (J. Clin.
Introduction
A considerable body of evidence indicates that short-term experimental hypercholesterolemia (HG)' caused by cholesterol Receivedfor publication and in revisedform.
1. Abbreviations used in this paper: CSD, cholesterol-supplemented diet; EDRF, endothelial-derived relaxing factor; HC, hypercholesterolemia; Kf, ultrafiltration coefficient; MAP, mean arterial pressure; ND, normal diet; NO, nitric oxide; PGC, glomerular capillary pressure; PLA2, phospholipase A2; QA, single nephron afferent plasma flow; RA, preglomerular resistance; RE, efferent resistance; RBF, renal blood flow; SNBF and SNFF, single nephron blood flow and filtration fraction, respectively. feeding leads to spontaneous arterial constriction and/or increased responsiveness to various vasoconstrictors (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The vascular beds studied include coronary, cerebral, aorta, hind limb, and renal arteries, and the phenomenon has been demonstrated both in vivo and in isolated vessel preparations studied in vitro. The cholesterol fraction responsible for the increase in vascular reactivity has been shown to be LDL (14, 15) , most likely LDL that has been oxidized either in vitro or in vivo (12, (15) (16) (17) (18) (19) (20) .
The mechanism by which oxidized LDL leads to increased vascular reactivity is not entirely clear, but appears to involve the endothelium, rather than the vascular smooth muscle (VSM). Thus, vasodilators that act directly on VSM, such as sodium nitroprusside, cause a normal degree of dilatation under hypercholesterolemic conditions (7, 13, 21, 22 ). In contrast, agents that release nitric oxide (NO) from the endothelium, such as acetylcholine, fail to induce normal vasodilatation under similar experimental conditions (3-6, 8, 1 1). Several different hypotheses have been proposed to explain these observations. It has been suggested that synthesis or release of NO is impaired by HC (23) (24) (25) . A second conclusion is that NO is synthesized normally or in excess but is metabolized more rapidly before acting on the VSM (22) . A third possibility is that HC increases the production and release of arachidonic acid pathway vasoconstrictors, which counteract the vasodilatory effect of NO.
The present study was undertaken to examine the latter hypothesis. Renal hemodynamic responses to acetylcholine, L-arginine, and a TxA2/PGH2 receptor antagonist were measured in rats fed a cholesterol supplemented diet (CSD) for 3 wk. The results suggest that the renal endothelium of CSD rats is able to synthesize NO from L-arginine when the latter is provided in excess, and that the VSM relaxes normally to the NO. Although vasodilatation due to acetylcholine was impaired, the response was markedly improved when TxA2/ PGH2 receptors were blocked. We postulate that acetylcholine, by causing a rise in intracellular calcium, activates phospholipase A2 (PLA2) and thus prostaglandin synthesis. Because elevations of LDL increase the supply ofarachidonic acid, activation of PLA2 could result in greater than normal amounts of TxA2/PGH2 synthesis and therefore impaired vasodilatation.
Methods
Male Sprague-Dawley rats weighing 225-275 g were maintained in individual metabolic cages and were fed a daily ration of25 g ofeither a regular normal rat diet (ND) or a pellet supplemented with 4% cholesterol and 1% cholic acid (CSD) (Teklad Premier Laboratory Diets, Madison, WI) for 3 wk, as previously described (12) . The composition of the two diets was exactly the same except for the cholesterol and cholic acid. Each animal consumed the entire 25 g/d. They had free
The surgical preparation ofthe animals on the day ofstudy and the micropuncture methods have been described previously (12, 26, 27) .
General anesthesia was induced by Inactin injection, 100 mg/kg body wt ip. Catheters were placed in a jugular vein for intravenous infusion, in a carotid artery for monitoring mean arterial pressure (MAP) and obtaining blood samples, and in the abdominal aorta via a femoral artery for infusion ofspecific agents (see below). The tip ofthis catheter was positioned -1 cm above the left renal artery, by direct visualization. The location of the catheter was confirmed by bolus injection of FD&C green dye which resulted in a flush ofthe kidneys. Blood flow to the left kidney was monitored continuously by an ultrasonic flow probe (Transonic Systems, Inc., Ithaca, NY) around the left main renal artery. GFR for both kidneys was measured by ['4C]inulin clearance via timed urine collections from the urinary bladder. The micropuncture measurements obtained from the left kidney were single nephron glomerular filtration rate (SNGFR), single nephron afferent plasma flow (QA), single nephron blood flow (SNBF), glomerular capillary pressure (Poc), proximal free-flow pressure, transcapillary hydraulic pressure, and single nephron filtration fraction (SNFF). The ultrafiltration coefficient (Kf) was derived from the mathematical model of Deen et al. (28) . Preglomerular resistance (RA) was calculated as previously described (12).
Group I: acetylcholine infusion. In six ND and six CSD rats, whole kidney and single nephron hemodynamic measurements were made during a control period while isotonic Ringer's solution was infused intravenously at arate of 1 ml/h per 100gbody wt. Afterthese measurements, acetylcholine (Sigma Chemical Co., St. Louis, MO) was infused into the aortic catheter above the two renal arteries at a constant rate of I ug/min. Repeat whole kidney and single nephron measurements were made during the acetylcholine infusion.
Group II: L-arginine infusion. In six ND and six CSD rats, control whole kidney and single nephron hemodynamic measurements were made, as in the group I animals. After completion of these measurements, L-arginine (Calbiochem-Behring Corp., San Diego, CA) was infused intravenously in a priming dose of 10 mg/kg followed by a constant infusion at a rate of 10 mg/kg per min. Repeat whole kidney and single nephron hemodynamic measurements were made during the L-arginine infusion.
Group III: thromboxane receptor antagonist and acetylcholine infusion. In four ND and six CSD rats, the TxA2 receptor antagonist, SK&F 96148 (kindly supplied by Smith, Kline & French Laboratories, Swedeland, PA), was infused into the aorta in a dose of 1 mg/kg, followed by a constant dose of 17 Ag/kg per min. Whole kidney and single nephron hemodynamic measurements were made during this infusion. After these measurements were completed, acetylcholine was added to the aortic infusion solution to deliver 1 j~g/min. Repeat whole kidney and single nephron measurements were made during this combined infusion. In four additional CSD rats, the same experimental protocol was followed except that the angiotensin II receptor antagonist, saralasin, was infused into the aorta (10 ,ug/kg bolus followed by 10 ag/kg per min) during period 1. Acetylcholine was then added to this solution during period 2.
Analytical methods. At the end of each experiment, blood was obtained from the aorta for measurement of total cholesterol, triglycerides, and HDL using quantitative enzymatic assays (Sigma Chemical Co.) (29, 30 
Results
Measurements of total serum cholesterol in the three groups of experiments are shown in Table I . Rats fed the ND had serum cholesterol levels ranging from 40 to 92 mg/dl. Those fed the CSD had serum cholesterol levels five to eight times higher, ranging from 250 to 590 mg/dl in individual animals. Fractionation of serum cholesterol, carried out in a previous study (12) , showed that the CSD caused marked increases in VLDL and LDL, but relatively small effects on HDL and fasting triglyceride levels.
Group I: acetylcholine infusion. The renal hemodynamic responses to infusion ofacetylcholine into the suorarenal aorta are shown in Table II . MAP was within the normal range in both the ND and CSD rats. Infusion of acetylcholine into the aorta resulted in a 4-mmHg decrease in MAP in the ND rats (P < 0.05) but no significant change in the CSD animals. As can be seen in Table II , during the control period (period 1), whole kidney and single nephron blood flow and filtration rate were significantly lower in the CSD rats than in the ND rats. In addition, QA and Kfwere lower and SNFF and PCC were higher in the CSD rats. These findings are closely comparable to data previously reported by our laboratory on the effect of CSD on renal hemodynamics (12) . With infusion of acetylcholine (period 2), a marked rise in renal blood flow (RBF), GFR, SNGFR, QA, SNBF, and Kf occurred in the ND rats, and RA fell. There was no significant effect on either Prc or SNFF. In the CSD animals, acetylcholine also caused significant changes in the same hemodynamic parameters, but the magnitude of response was much smaller. Moreover, all of the flow values during period 2 in the CSD rats remained significantly below the period 2 values in the ND rats, and RA remained higher (P <0.05).
Percent increases in SNGFR and QA and decreases in RA due to acetylcholine are illustrated in Fig. 1 . In the ND rats, SNGFR and QA rose by 24-27%. In sharp contrast, in the CSD rats, acetylcholine induced a rise of only 10-15%. The percent decrease in RA was also markedly blunted in the CSD animals. Group II: L-arginine infusion. Table III presents the renal hemodynamic data for the experiments in which L-arginine was infused during period 2. There were no significant effects of L-arginine infusion on MAP. As can be seen in the table, in the ND rats L-arginine caused marked increases in RBF, GFR, SNGFR, QA, SNBF, and Kf, but did not alter SNFF or PGc. RA fell significantly. In the CSD rats, the L-arginine infusion caused quantitatively similar changes in all of these hemodynamic parameters and, in addition, a significant fall in SNFF.
The absolute values for GFR, SNFF, SNBF, and RA were statistically equal to those in the ND rats, but those for RBF, SNGFR, PGC and Kf remained significantly different. The per- cent changes for some of the hemodynamic parameters that occurred with L-arginine infusion are shown in Fig. 2 . As is shown, changes in SNGFR and RA were similar in ND and CSD animals, whereas the rise in QA was actually greater in the CSD rats than in the ND rats.
Group III: TxA2 receptor antagonist-acetylcholine infusion. In Table IV are shown the renal hemodynamic responses to acetylcholine in ND and CSD rats infused with the TxA2/ PGH2 receptor antagonist SK&F 96148 before acetylcholine administration. During period 1, all ofthe renal hemodynamic measurements were statistically the same in these two groups of animals. Thus, the TxA2 receptor antagonist had presumably restored to normal the hemodynamic values of the CSD animals. This is in agreement with previously published findings from our laboratory (12) . During period 2, when acetylcholine was added to the TxA2/PGH2 antagonist infusion, significant increases in RBF, GFR, SNGFR, QA, and SNBF occurred in both groups, and RA fell significantly. The percent changes in SNGFR, QA, and RA for CSD rats infused with acetylcholine±TxA2/PGH2 antagonist are shown in Fig. 3 . It is evident that the presence ofthe receptor antagonist markedly increased the response to acetylcholine in these animals. The receptor antagonist appeared to also enhance the response to acetylcholine in the ND rats. This is shown in Table V, where the data for   period 2 from Tables II and IV (Table II) .
Discussion
Short-term HC has been found to increase vascular tone and the reactivity to vasoconstrictors in a number of vascular beds ( 1-13), including the renal blood vessels (12) . In vitro studies indicate that oxidized LDL and, to a lesser extent, VLDL are responsible for the abnormalities (14, 15) . Because the abnormal reactivity occurs after a relatively brief exposure of blood vessels to cholesterol, when endothelial pathology or fatty streaks have not yet developed, the impaired response is thought to be due to functional rather than structural changes. The most characteristic abnormality described in several different vascular beds is a blunted vasodilatory response to acetylcholine (3-6, 8, 1 1) .
The present experiments demonstrate that the renal blood vessels in CSD rats also have a blunted response to acetylcholine. As shown in Table II and Fig. 1 , infusion of acetylcholine into the aorta of HC rats resulted in only relatively small increases in RBF and GFR compared with rats on a ND. In the ND rats, single nephron hemodynamic measurements demonstrated increases in SNBF and QA, which were due to a significant fall in RA. In In the HC rats, blood flow and filtration rates were significantly lower than in the ND animals during the control period, findings in agreement with a previously published study by our laboratory (12) . When acetylcholine was infused into the aorta of these animals (Table II) , a significant vascular relaxation at pre-and postglomerular sites occurred, but the response was much less than in the ND rats (Table II and Fig. 1 ).
To determine whether this blunted response to acetylcholine was due to a limited capacity of the renal endothelium to synthesize or release NO, we infused L-arginine, the normal endogenous precursor of NO synthesis. The results, shown in Table III and Fig. 2 , indicate that in the ND rats, renal blood vessels dilate markedly in response to L-arginine. RBF, GFR, SNBF, and QA increased strikingly, as did SNGFR. This was accompanied by a fall in RA but no significant change in PGC or SNFF. This combination of findings suggests that RE fell in proportion to the fall in RA. Kf rose, which contributed to the increase in filtration rate. Thus, the renal vascular responses to infusion of L-arginine in the ND rats were qualitatively similar to those induced by acetylcholine.
In the HC rats, L-arginine infusion resulted in a degree of renal vasodilatation that was quantitatively comparable to that in the ND rats (Table III) . GFR, SNBF, QA, and RA all reached values that were not significantly different from those in the ND rats. As shown in Fig. 2 , the percent changes in SNGFR, QA, and RA with L-arginine infusion were as great if not greater than in the ND rats. These findings could be interpreted to mean that there is a deficiency ofendogenous L-arginine in HC rats. Alternatively, the findings are consistent with impaired enzymatic synthesis of NO from endogenous L-arginine, but this can be overcome by administration of a large amount of L-arginine. Several other investigators have examined the effect of L-arginine administration on the impaired vasodilatation of blood vessels removed from HC animals. Cooke et al. (23) infused L-arginine into HC rabbits for 70 min and then studied their excised thoracic aortic rings in vitro. They found that the L-arginine infusion (but not D-arginine) normalized the in vitro relaxation response of the rings to acetylcholine. Infusion of L-arginine in normal rabbits had no effect on the relaxation response of their aortic rings. The same laboratory demonstrated that cerebral basilar arteries from HC rabbits manifested impaired relaxation in response to acetylcholine and that in vitro exposure of the arteries to L-arginine normalized the acetylcholine response (24). In an in vivo study of femoral artery blood flow in HC rabbits, these investigators found that L-arginine augmented the vasodilatation response to acetylcholine (25) . They suggested that HC may induce a reversible reduction in intracellular arginine availability or metabolism, which was corrected by exogenous L-arginine. Our observations are in accord with their results. However, Minor et al. (22) directly measured the in vitro release of NO from the aortas of HC rabbits by chemiluminescence and found it to be markedly increased. Addition of acetylcholine caused a further increase in NO release. In spite of this, they found, in a bioassay organ chamber, that the NO released by aortas from HC rabbits failed to cause relaxation of downstream normal detector vessels. They concluded, therefore, that HC does not impair NO synthesis, but it may cause loss of incorporation of NO into another vasoactive compound, or it accelerates the rate of degradation of endothelial-derived relaxing factor (EDRF). Thus, a specific abnormality in EDRF metabolism has not yet been identified in HC animals.
Because it is well established that HC increases thromboxane production and aggregation of platelets (31-33) and in- (Table II) , period 2 data for CSD all significantly different from period 2 for CSD rats given acetylcholine alone (Table II) .
creases urinary excretion ofTxB2 (12), we examined the role of TxA2 in the impaired vasodilator response to acetylcholine. These experiments, shown in Table IV In contrast to these studies, it has been found that endotheHal-produced TxA2/PGH2 can interfere with the relaxation response to acetylcholine in two different experimental models, i.e., vessels from SHR rats and vessels exposed to high glucose concentrations. Luscher and Vanhoutte (34) found that aortic rings from SHR rats failed to dilate normally in response to acetylcholine and that this was normalized by cyclooxygenase inhibition, but not thromboxane synthetase or leukotriene synthetase inhibition. They concluded that the impaired relaxation was due to release of an endothelial contracting factor (Table V) . We conclude, therefore, that acetylcholine administration evokes release ofvasoconstrictor prostanoids as well as NO, and the hemodynamic response is the net effect of these opposing vasoactive substances.
Because elevated levels of LDL enrich cell membranes with cholesterol and arachidonic acid (37), activation of PLA2 in endothelial cells would be expected to generate larger than normal amounts ofprostaglandins. We propose that this accounts in large part for the impaired vasodilatory response to acetylcholine observed in the cholesterol-fed rats.
Blockade of All receptors with saralasin did not restore responsiveness to acetylcholine, as did blockade of TxA2 receptors (Table VI) . However, saralasin did improve renal hemodynamics slightly in the CSD rats, suggesting a minor role for All in the hemodynamic abnormalities of the CSD animals.
Although TxA2/PGH2 blockade improved the renal vasodilatory response to acetylcholine in the CSD rats, the absolute levels of single nephron flow rates did not reach those in the ND rats infused with the same combination ofTxA2 antagonist + acetylcholine. The data for these two groups are compared statistically in Table VI . It is evident that most values were significantly different in the CSD rats versus the ND rats. It appears, therefore, that an additional abnormality existed in the CSD animals, not completely corrected by blocking TxA2/ PGH2 receptors. The nature of this additional factor is not clear, but it could be a defect in NO metabolism or an abnormality in other vasodilator or vasoconstrictor chemicals.
The clinical implications of these findings with regard to renal disease is uncertain. Long-term HC has been shown to exacerbate renal injury in several different models of renal disease (38, 39) . The mechanism is unknown, but may involve activation of growth factors and prostanoids, as well as causing hemodynamic changes (39) . Thromboxane has been shown to have direct effects on glomerular mesangial cells (40) and the synthesis of extracellular matrix (41) . It seems possible, therefore, that the increased thromboxane synthesis induced by HC contributes to accelerated glomerular injury found when HC coexists with intrinsic renal disease.
